Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors

SIMPLE SUMMARY: The lung cancer treatment paradigm has been completely changed by immunotherapy; however, less than half of the treated patients obtain a response, and an even smaller proportion achieve a long survival. Primary and acquired resistance mechanisms and the immune-related adverse events...

Descripción completa

Detalles Bibliográficos
Autores principales: Catalano, Martina, Shabani, Sonia, Venturini, Jacopo, Ottanelli, Carlotta, Voltolini, Luca, Roviello, Giandomenico
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777293/
https://www.ncbi.nlm.nih.gov/pubmed/36551630
http://dx.doi.org/10.3390/cancers14246145

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9777293/
https://www.ncbi.nlm.nih.gov/pubmed/36551630
http://dx.doi.org/10.3390/cancers14246145

Ejemplares similares